Literature DB >> 26363781

Clinicopathological outcomes of preoperative chemoradiotherapy using S-1 plus Irinotecan for T4 lower rectal cancer.

Naohito Beppu1, Hidenori Yoshie2, Fumihiko Kimura2, Tsukasa Aihara2, Hiroshi Doi3, Norihiko Kamikonya3, Nagahide Matsubara4, Naohiro Tomita4, Hidenori Yanagi2, Naoki Yamanaka2.   

Abstract

PURPOSE: To investigate the clinicopathological outcomes of patients with T4 lower rectal cancer treated using preoperative chemoradiotherapy with S-1 plus Irinotecan.
METHODS: Between 2005 and 2011, 35 patients with T4M0 lower rectal cancer, diagnosed initially as T4a in 12 and as T4b in 23, were treated with 45 Gy of radiotherapy concomitantly with S-1 plus Irinotecan. The median follow-up period was 50.6 months (range 2-123 months).
RESULTS: A total of 32 patients (91.4 %) completed the radiotherapy and 26 (74.3 %) completed the full chemotherapy regimen. Radical surgery was then performed in 33 (94.3 %) of the 35 patients after the exclusion of two patients, who had macroscopic residual disease. The pathological diagnosis was downstaged from T4a to ypT0-3 in all 12 of those patients (100 %) and from T4b to ypT0-4a in 20 of those 23 patients (87.0 %). The tumor regression grade of 1a/1b/2/3 (complete response) was 10/8/15/2, respectively. In terms of long-term survival, the 5-year local relapse-free survival rate was 74.8 % and the recurrence-free survival rate was 52.0 %.
CONCLUSIONS: This regimen may result in favorable downstaging. Moreover, in this series, pathological evidence of involvement of adjacent organs was rare following preoperative chemoradiotherapy, in the patients with disease diagnosed as T4b at the initial staging.

Entities:  

Keywords:  Oncologic outcomes; Preoperative chemoradiotherapy; S-1 plus Irinotecan; T4 lower rectal cancer

Mesh:

Substances:

Year:  2015        PMID: 26363781     DOI: 10.1007/s00595-015-1250-z

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  28 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Risk factors for symptomatic anastomotic leakage after low anterior resection for rectal cancer with 30 Gy/10 f/2 w preoperative radiotherapy.

Authors:  Lin Wang; Jin Gu
Journal:  World J Surg       Date:  2010-05       Impact factor: 3.352

3.  Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation.

Authors:  Ovidio Hernando-Requejo; Mercedes López; Antonio Cubillo; Almudena Rodriguez; Raquel Ciervide; Jeannette Valero; Emilio Sánchez; Mariola Garcia-Aranda; Jesus Rodriguez; Guillermo Potdevin; Carmen Rubio
Journal:  Strahlenther Onkol       Date:  2014-04-09       Impact factor: 3.621

4.  Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study.

Authors:  Luciana Caravatta; Gilbert D A Padula; Vincenzo Picardi; Gabriella Macchia; Francesco Deodato; Mariangela Massaccesi; Luigi Sofo; Fabio Pacelli; Fabio Rotondi; Giuseppe Cecere; Giuseppina Sallustio; Liberato Di Lullo; Adele Piscopo; Samantha Mignogna; Pierluigi Bonomo; Numa Cellini; Vincenzo Valentini; Alessio G Morganti
Journal:  Acta Oncol       Date:  2011-08-18       Impact factor: 4.089

5.  Bladder-sparing extended resection of locally advanced rectal cancer involving the prostate and seminal vesicles.

Authors:  Norio Saito; Takanori Suzuki; Masanori Sugito; Masaaki Ito; Akihiro Kobayashi; Toshiyuki Tanaka; Masahito Kotaka; Hirokazu Karaki; Takaya Kobatake; Yoshiyuki Tsunoda; Akio Shiomi; Masaaki Yano; Nozomi Minagawa; Yuji Nishizawa
Journal:  Surg Today       Date:  2007-09-26       Impact factor: 2.549

6.  Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial.

Authors:  M Kusters; C A M Marijnen; C J H van de Velde; H J T Rutten; M J Lahaye; J H Kim; R G H Beets-Tan; G L Beets
Journal:  Eur J Surg Oncol       Date:  2010-01-21       Impact factor: 4.424

7.  Outcomes of clinical T4M0 extra-peritoneal rectal cancer treated with preoperative radiochemotherapy and surgery: a prospective evaluation of a single institutional experience.

Authors:  Vincenzo Valentini; Claudio Coco; Gianluca Rizzo; Alberto Manno; Antonio Crucitti; Claudio Mattana; Carlo Ratto; Alessandro Verbo; Fabio M Vecchio; Brunella Barbaro; Maria A Gambacorta; Caterina Montoro; Maria C Barba; Luigi Sofo; Valerio Papa; Roberta Menghi; Domenico M D'Ugo; Giovanbattista Doglietto
Journal:  Surgery       Date:  2009-03-21       Impact factor: 3.982

Review 8.  Early and late toxicity of radiotherapy for rectal cancer.

Authors:  Ines Joye; Karin Haustermans
Journal:  Recent Results Cancer Res       Date:  2014

9.  Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer.

Authors:  Yuichiro Yoshioka; Keisuke Uehara; Tomoki Ebata; Yukihiro Yokoyama; Ayako Mitsuma; Yuichi Ando; Masato Nagino
Journal:  Surg Today       Date:  2013-08-14       Impact factor: 2.549

10.  Pelvic exenteration for clinical T4 rectal cancer: oncologic outcome in 93 patients at a single institution over a 30-year period.

Authors:  Seiji Ishiguro; Takayuki Akasu; Shin Fujita; Seiichiro Yamamoto; Miranda Kusters; Yoshihiro Moriya
Journal:  Surgery       Date:  2008-12-23       Impact factor: 3.982

View more
  2 in total

1.  TU-100 exerts a protective effect against bacterial translocation by maintaining the tight junction.

Authors:  Chie Takasu; Wubetu Gizachew Yismaw; Nobuhiro Kurita; Kozo Yoshikawa; Hideya Kashihara; Toru Kono; Mitsuo Shimada
Journal:  Surg Today       Date:  2017-04-18       Impact factor: 2.549

2.  Effect of TU-100 on Peyer's patches in a bacterial translocation rat model.

Authors:  Chie Takasu; Katsuki Miyazaki; Kozo Yoshikawa; Masaaki Nishi; Takuya Tokunaga; Hideya Kashihara; Toshiaki Yoshimoto; Hirohisa Ogawa; Yuji Morine; Mitsuo Shimada
Journal:  Ann Gastroenterol Surg       Date:  2021-04-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.